Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan-Bismuth Quadruple Therapy for Second-Line H. Pylori Eradication
NCT07855497Active, not recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Feb 2021
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Randomised trial of tegoprazan in Helicobacter pylori infection (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Efficacy of H. pylori eradication at 4 weeks. Started Feb 2021; status: active, not recruiting.
02
Drugs
tegoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07855497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07855497.